Teva Pharmaceutical Industries Ltd
TEVA16.900USD
+0.120+0.72%
Market hours （ET）Quotes delayed by 15 min
19.16BMarket Cap
LossP/E TTM
More Details of Teva Pharmaceutical Industries Ltd Company
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Company Info
Company codeTEVA
Company nameTeva Pharmaceutical Industries Ltd
IPO dateJan 01, 1951
Founded at1944
CEOMr. Richard D. Francis
Number of employees33892
Security typeOrdinary Share
Fiscal year-endJan 01
Address124 Dvora Hanevi'a St.
CityTEL AVIV-YAFO
Stock exchangeTel Aviv Stock Exchange
CountryIsrael
Postal code6944020
Phone97239148213
Websitehttps://www.tevapharm.com/
Company codeTEVA
IPO dateJan 01, 1951
Founded at1944
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Christine (Chris) Fox
Ms. Christine (Chris) Fox
Executive Vice President - U.S. Commercial
Executive Vice President - U.S. Commercial
14.28K
--
Prof. Varda Shalev
Prof. Varda Shalev
Independent Director
Independent Director
12.87K
--
Mr. David R. McAvoy
Mr. David R. McAvoy
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
11.91K
--
Mr. Evan Lippman
Mr. Evan Lippman
Executive Vice President - Business Development
Executive Vice President - Business Development
--
--
Mr. Placid Jover
Mr. Placid Jover
Executive Vice President, Chief Human Resources Officer
Executive Vice President, Chief Human Resources Officer
--
--
Mr. Richard Daniell
Mr. Richard Daniell
Executive Vice President - European Commercial
Executive Vice President - European Commercial
--
--
Mr. Eliyahu Sharon (Eli) Kalif
Mr. Eliyahu Sharon (Eli) Kalif
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Matthew Shields
Mr. Matthew Shields
Executive Vice President - Teva Global Operations
Executive Vice President - Teva Global Operations
--
--
Mr. Chen Lichtenstein
Mr. Chen Lichtenstein
Independent Director
Independent Director
--
--
Dr. Sol J. Barer, Ph.D.
Dr. Sol J. Barer, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Christine (Chris) Fox
Ms. Christine (Chris) Fox
Executive Vice President - U.S. Commercial
Executive Vice President - U.S. Commercial
14.28K
--
Prof. Varda Shalev
Prof. Varda Shalev
Independent Director
Independent Director
12.87K
--
Mr. David R. McAvoy
Mr. David R. McAvoy
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
11.91K
--
Mr. Evan Lippman
Mr. Evan Lippman
Executive Vice President - Business Development
Executive Vice President - Business Development
--
--
Mr. Placid Jover
Mr. Placid Jover
Executive Vice President, Chief Human Resources Officer
Executive Vice President, Chief Human Resources Officer
--
--
Mr. Richard Daniell
Mr. Richard Daniell
Executive Vice President - European Commercial
Executive Vice President - European Commercial
--
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Generic products
9.46B
57.19%
AUSTEDO
1.69B
10.20%
Anda
1.54B
9.28%
Other
1.38B
8.32%
AJOVY
507.00M
3.06%
Other
1.98B
11.94%
By RegionUSD
Name
Revenue
Proportion
United States
8.03B
48.56%
Europe
5.10B
30.85%
International Markets
2.46B
14.89%
Other
944.00M
5.71%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Generic products
9.46B
57.19%
AUSTEDO
1.69B
10.20%
Anda
1.54B
9.28%
Other
1.38B
8.32%
AJOVY
507.00M
3.06%
Other
1.98B
11.94%
Shareholder
Update time: Sat, May 17
Update time: Sat, May 17
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Fidelity Management & Research Company LLC
6.57%
Ion Asset Management Israel Ltd
3.40%
Clal Insurance Enterprises Holdings Ltd.
3.30%
BlackRock Institutional Trust Company, N.A.
2.88%
Menora Mivtachim Insurance Ltd.
2.55%
Other
81.31%
Shareholder Statistics
Shareholder
Proportion
Fidelity Management & Research Company LLC
6.57%
Ion Asset Management Israel Ltd
3.40%
Clal Insurance Enterprises Holdings Ltd.
3.30%
BlackRock Institutional Trust Company, N.A.
2.88%
Menora Mivtachim Insurance Ltd.
2.55%
Other
81.31%
Type
Shareholder
Proportion
Investment Advisor
27.45%
Hedge Fund
13.25%
Investment Advisor/Hedge Fund
11.80%
Insurance Company
4.85%
Research Firm
2.85%
Pension Fund
1.65%
Family Office
1.32%
Bank and Trust
0.83%
Sovereign Wealth Fund
0.22%
Other
35.77%
Institutional Shareholding
Update time: Mon, Jan 20
Update time: Mon, Jan 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
1095
724.51M
63.17%
+11.84M
2024Q4
1087
683.52M
59.66%
-22.86M
2024Q3
1029
663.95M
58.60%
-6.13M
2024Q2
1002
631.05M
55.72%
-26.20M
2024Q1
950
595.83M
53.15%
-34.73M
2023Q4
932
601.27M
53.63%
+7.51M
2023Q3
929
573.53M
51.16%
-84.22M
2023Q2
921
512.98M
45.79%
-122.32M
2023Q1
927
576.84M
51.93%
-50.26M
2022Q4
946
573.39M
51.61%
-69.40M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
76.01M
6.63%
+14.91M
+24.41%
Dec 31, 2024
Ion Asset Management Israel Ltd
36.65M
3.2%
+409.78K
+1.13%
Dec 31, 2024
Clal Insurance Enterprises Holdings Ltd.
38.96M
3.4%
+4.42M
+12.79%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
33.10M
2.89%
+786.74K
+2.43%
Dec 31, 2024
Menora Mivtachim Insurance Ltd.
28.38M
2.48%
-456.80K
-1.58%
Dec 31, 2024
Lingotto Investment Management LLP
27.19M
2.37%
+688.86K
+2.60%
Dec 31, 2024
Phoenix Investment and Finances Ltd
21.21M
1.85%
-1.35M
-5.98%
Dec 31, 2024
Migdal Insurance and Financial Holdings Ltd
26.04M
2.27%
+569.41K
+2.24%
Dec 31, 2024
Rubric Capital Management LP
17.00M
1.48%
+994.50K
+6.21%
Dec 31, 2024
View more
Related ETFs
Update time: 11 hours ago
Update time: 11 hours ago
Name
Proportion
VanEck Israel ETF
7.57%
iShares MSCI Israel ETF
6.8%
Tema Neuroscience and Mental Health ETF
4.42%
VanEck Pharmaceutical ETF
4.34%
Amplify Weight Loss Drug & Treatment ETF
4.05%
ARK Israel Innovative Technology ETF
1.94%
AdvisorShares Dorsey Wright ADR ETF
1.81%
Janus Henderson Securitized Income ETF
0.87%
WisdomTree International Multifactor Fund
0.58%
iShares MSCI Intl Value Factor ETF
0.41%
View more
VanEck Israel ETF
Proportion7.57%
iShares MSCI Israel ETF
Proportion6.8%
Tema Neuroscience and Mental Health ETF
Proportion4.42%
VanEck Pharmaceutical ETF
Proportion4.34%
Amplify Weight Loss Drug & Treatment ETF
Proportion4.05%
ARK Israel Innovative Technology ETF
Proportion1.94%
AdvisorShares Dorsey Wright ADR ETF
Proportion1.81%
Janus Henderson Securitized Income ETF
Proportion0.87%
WisdomTree International Multifactor Fund
Proportion0.58%
iShares MSCI Intl Value Factor ETF
Proportion0.41%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
